Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection

Authors

  • Ioannis Griveas Medical Director and Consultant Nephrologist, Nephrology Department, Army Share Fund Hospital of Athens, Greece, 417 NIMTS https://orcid.org/0000-0003-3588-8532
  • Antonios Schoinas Consultant Nephrologist, Nephrology Department, Army Share Fund Hospital of Athens, Greece, 417 NIMTS https://orcid.org/0000-0002-5836-7601
  • Anthi Balitsari Consultant Nephrologist, Nephrology Department, Army Share Fund Hospital of Athens, Greece, 417 NIMTS https://orcid.org/0000-0001-6951-0875
  • Gerasimos Asimakopoulos Resident in Nephrology, Nephrology Department, Army Share Fund Hospital of Athens, Greece, 417 NIMTS
  • Evaggelos Pratilas Resident in Nephrology, Nephrology Department, Army Share Fund Hospital of Athens, Greece, 417 NIMTS

DOI:

https://doi.org/10.3126/ajms.v12i7.36499

Keywords:

Hemodialysis, Covid-19, Soluble urokinase plasminogen receptor (suPAR)

Abstract

Background: Soluble urokinase plasminogen receptor (suPAR) is a protein in the blood that has been described to reflect the severity status of systemic inflammation.

Aims and Objective: We investigated the association between admission suPAR levels and severity and outcome of HD patients with Covid-19 infection.

Materials and Methods: In an observational study of adult HD patients hospitalized for Covid-19, we measured suPAR levels in plasma samples. The time table for those measurements were as follows: at the beginning of admission, after hemoperfusion (HP) session for those patients that received them, and just before discharge.

Results: Of the 17 patients (7 were male), 13 patients received HP (mean age: 74 years old). The median suPAR level was 12.94 ng/ml. For those who undertook HP in HD unit median suPAR level was before session 12.95 ng/mil and 6.2 ng/ml at the end of each session (p<0.05). 3 patients had suPAR level below 7 ng/ml. 2 of them survived without developing pleural effusions. 7 patients discharged from the hospital with median suPAR level 12.08 ng/ml which did not differ significantly from the median suPAR level of the diceased ones (13.68 ng/ml).

Conclusion: Admission of suPAR levels in HD patients hospitalized for Covid-19 do not seem to be predictive for their clinical course in general. Chronic Kidney Disease and its relation to suPAR independently of patients’ inflammation status may be the key component for our notice. Despite that, in patients where low levels of suPAR combined with absence of pleural effusions the prognosis was excellent.

Downloads

Download data is not yet available.
Abstract
183
PDF
275

Downloads

Published

2021-07-01

How to Cite

Griveas, I., Schoinas, A., Balitsari, A., Asimakopoulos, G., & Pratilas, E. (2021). Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection. Asian Journal of Medical Sciences, 12(7), 1–4. https://doi.org/10.3126/ajms.v12i7.36499

Issue

Vol. 12 No. 7 (2021)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).